1 Min Read
April 30 (Reuters) - Amgen Inc:
* AMGEN RECEIVES POSITIVE CHMP OPINION TO ADD OVERALL SURVIVAL RESULTS FROM THE PHASE 3 ASPIRE STUDY TO KYPROLIS® (CARFILZOMIB) LABEL Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.